IF 2.5 3区医学

Transfusion Pub Date : 2025-07-01 DOI: 10.1111/trf.18321

Swati Kulkarni, Anisha Navkudkar, Naga Muralidhar Merugu, Priti Desai

引用次数: 0

Evaluation of a microfluidic chip-based cell sorter in clinical manufacturing processes to deplete or isolate CD4 regulatory T cells. 评估基于微流控芯片的细胞分选器在临床制造过程中消耗或分离CD4调节性T细胞。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-30 DOI: 10.1111/trf.18324

Ruud Hulspas, M Felicia Ciuculescu, Carolina Sasso, Baochun Zhang, José A Cancelas, Jerome Ritz

{"title":"Evaluation of a microfluidic chip-based cell sorter in clinical manufacturing processes to deplete or isolate CD4 regulatory T cells.","authors":"Ruud Hulspas, M Felicia Ciuculescu, Carolina Sasso, Baochun Zhang, José A Cancelas, Jerome Ritz","doi":"10.1111/trf.18324","DOIUrl":"https://doi.org/10.1111/trf.18324","url":null,"abstract":"Background: Clinical scale manufacturing for cell therapies requires reliable methods to purify specific cell types. Few microfluidic chip-based cell sorters have been integrated into manufacturing processes of therapeutic cells. Reports have highlighted the need to assess current requirements and explore areas for improvement.Study design and methods: We evaluated Highway1, a new microfluidic chip-based cell sorter in the context of good manufacturing practice (GMP)-compliant manufacturing processes involving purification of CD4 T cell subsets. Tests explored throughput and processing time limits, as required in GMP-compliant purification of regulatory T cells (Tregs) and of CD4 T cells free of CD4 Tregs. Findings were used to establish conditions with the best balance between processing time and yield.Results: Best average recovery (60%) was obtained when processed at 1-1.5 million cells/mL, purifying a target population of 33%. Weighing recovery against processing time, a sample concentration of 2.0 million cells/mL offers the optimum condition for sorting CD4 T cells free of CD4 Tregs from healthy blood. Similar tests also show that this device allows for shorter overall processing times to purify CD4 Tregs than previously reported for other microfluidic chip-based sorters, with the additional benefit of an essentially user intervention-free operation.Discussion: The Highway1 allows for reliable selection of a highly pure subpopulation of CD4 T cells in a GMP-compliant, cell therapy manufacturing setting. As with conventional sorters, the purification process for Tregs still needs to be preceded by a pre-enrichment process to keep the total processing time within an acceptable range for clinical-grade cell manufacturing.","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

It is time to eliminate the one-hour corrected count increment in the diagnostic workup of platelet transfusion refractoriness. 是时候在血小板输注难治性诊断检查中消除1小时校正计数增量了。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-30 DOI: 10.1111/trf.18327

Raeshun Glover, Bettie Yeboah, Ralph R Vassallo, Moritz Stolla, Sandhya R Panch, Jenna Khan, Valery J Kogler, Chance John Luckey, James D Gorham

引用次数: 0

West Nile Virus positivity amongst Canadian blood donors and effectiveness of off-season screening. 西尼罗病毒在加拿大献血者中的阳性和淡季筛查的有效性。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-28 DOI: 10.1111/trf.18326

Carmen L Charlton, Steven J Drews, Kai Makowski, Gordon Hawes, Cynthia Cranney, Alyssia Robinson, Heidi Wood, Mark Bigham, Sheila F O'Brien

{"title":"West Nile Virus positivity amongst Canadian blood donors and effectiveness of off-season screening.","authors":"Carmen L Charlton, Steven J Drews, Kai Makowski, Gordon Hawes, Cynthia Cranney, Alyssia Robinson, Heidi Wood, Mark Bigham, Sheila F O'Brien","doi":"10.1111/trf.18326","DOIUrl":"https://doi.org/10.1111/trf.18326","url":null,"abstract":"Background: We sought to examine the prevalence of West Nile Virus (WNV) nucleic acid test (NAT) positivity over time in Canadian blood donors, examine the level of false-positive NAT screening, and understand the effectiveness of travel-related testing outside of WNV seasonality in Canada.Study design and methods: All blood donations in Canada (except Québec) between 2018 and 2023 were tested by the Roche Cobas WNV-NAT assay during the summer-fall season by Canadian Blood Services. Testing for recent travel outside Canada was performed in the winter-spring season. All 2023 WNV-NAT-positives were confirmed by two independent WNV-specific polymerase chain reaction (PCRs).Results: While WNV positivity varied by location and time, no increasing trend of positivity was observed over the 6-year study period. No WNV-NAT-positive donors with a history of recent travel outside of Canada in the winter-spring season were identified by donor screening (2018-2023). In total, 2,454,102 samples were tested during summer months and 267,988 in winter months. In 2023, WNV-specific PCR confirmed 10 of 13 (76.9%) screening WNV-NATs. Recent Japanese Encephalitis Virus (JEV) vaccination was identified as a potential false positive for initial WNV screening results.Discussion: Between 2018 and 2023, WNV-NAT positivity amongst Canadian blood donors remained stable, with no evidence of an increasing positivity trend. The utility of off-season travel-related testing may be limited, as no donors were identified during the six-year study timeframe. Finally, confirmation testing using WNV-specific PCR is recommended to identify true cases and to limit misidentification of other genetically similar viruses, such as JEV.","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rising transfusion rates amidst stable blood supply: A Canadian perspective on emerging challenges for blood operators. 在稳定的血液供应中不断上升的输血率：加拿大对血液运营商面临的新挑战的看法。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-27 DOI: 10.1111/trf.18325

An Duong, Sheharyar Raza, Marianne Waito, Tanya Petraszko, Asim Q Alam

引用次数: 0

The novel JK*02(588G;929G) allele in an Indian patient dramatically impairs the expression of the Jk^b antigen. 一名印度患者的新型JK*02（588G;929G）等位基因显著损害了Jkb抗原的表达。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-25 DOI: 10.1111/trf.18319

Caroline Bénech, Clélia Mornet, Laurence Delugin, Delphine Steiger, Christine Guerry, Laurence Le Glatin, Isabelle Dupont, Cédric Le Maréchal, Yann Fichou

引用次数: 0

A new blood group antigen in the Knops blood group system: KNEH. Knops血型系统中一种新的血型抗原：KNEH。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-25 DOI: 10.1111/trf.18322

Lisa Weidner, Xaver Fanninger, Elke Nowak, Georg Gratz, Wolfgang Allhoff, Hanja Tyrakowski, Erwin Scharberg, Christof Jungbauer

引用次数: 0

Hemostatic and thrombotic outcomes in patients undergoing therapeutic plasma exchange. 接受治疗性血浆交换的患者的止血和血栓结局。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-25 DOI: 10.1111/trf.18320

Sirui Ma, Rushad Patell, Laura Dodge, Shengling Ma, Michelle Knox, Brian J Carney

{"title":"Hemostatic and thrombotic outcomes in patients undergoing therapeutic plasma exchange.","authors":"Sirui Ma, Rushad Patell, Laura Dodge, Shengling Ma, Michelle Knox, Brian J Carney","doi":"10.1111/trf.18320","DOIUrl":"https://doi.org/10.1111/trf.18320","url":null,"abstract":"Background: Whether therapeutic plasma exchange (TPE) results in clinically relevant bleeding or thrombotic events is not well characterized.Study design and methods: We conducted a single-institution retrospective cohort study to estimate the incidence of bleeding and thrombotic outcomes of patients treated with TPE from 2017 to 2021. Patients with ≥3 treatment sessions within a 14-day period were included. Two independent physician reviewers manually reviewed patient charts. We calculated the 30-day cumulative incidence of bleeding and thrombotic outcomes with 95% confidence intervals (CI). We used a regression model to determine the association between clinical and laboratory features and study outcomes.Results: The study comprised 145 patients who underwent 176 treatment courses, representing a cumulative total of 890 individual TPE procedures. The cumulative incidence of clinically relevant bleeding (including major bleeding and clinically relevant nonmajor bleeding) was 8.0% (95% CI 4.4%-13.0%), and thrombosis was 4.0% (95% CI 1.6%-8.0%). There was one fatal bleeding event. Older age and chronic kidney disease were associated with odds ratios of 1.08 (95% CI 1.03-1.13, p = .002) and 4.68 (95% CI 1.33-14.90, p = .01), respectively, for bleeding. Patients who received any quantity of fresh frozen plasma as replacement fluid had a bleeding rate of 16.4% compared to 6.6% in patients who did not receive plasma (p = .05).Discussion: TPE-associated bleeding complications occur at a higher rate than previously understood. Further prospective investigations are merited to characterize bleeding risk factors and optimal preventive strategies.","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The African blood donor study: Study design and pilot experience from the BLOODSAFE program. 非洲献血者研究：血液安全项目的研究设计和试点经验。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-24 DOI: 10.1111/trf.18311

Meghan Delaney, Lucy Asamoah-Akuoko, Jana MacLeod, Bridon M'baya, Bernard Appiah, Yvonne Dei-Adomakoh, Alfred Edwin Yawson, Emmanuel Nene Dei, Cindy Makanga, Abdirahman Musa, Tecla Chelagat, Kevin Ochieng, Titus Chiwindo, Maganizo Chagomerana, Juan Carlos Puyana, Pratap Kumar, Mina C Hosseinipour, Susan Telke, Cavan Reilly

引用次数: 0

Haemolytic transfusion reaction due to anti-A₁ in a group O patient who received allogeneic stem cell transplantation from a group A donor. 1例接受a组供体异体干细胞移植的O组患者抗a1引起的溶血性输血反应。

IF 2.5 3区医学

Transfusion Pub Date : 2025-06-24 DOI: 10.1111/trf.18314

Alexander Owen Taylor, Ulrik Sprogøe

引用次数: 0

Transfusion最新文献